Stock Market News3 months Elite Pharmaceuticals’ Stock Up Despite Q2 Earnings Decline Zacks
ELTP sees strong revenue growth despite a net loss, driven by new product launches and strategic acquisitions.
Earnings · Pharmaceuticals · S&P 500
XELTP sees strong revenue growth despite a net loss, driven by new product launches and strategic acquisitions.
Earnings · Pharmaceuticals · S&P 500
X